A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.
This study is testing a medication called Epcoritamab to see if it can help patients who have already had some success treating their CLL or SLL. It aims to see if this treatment can clear up the tiny amounts of cancer that remain after initial therapy.
You may be eligible if you are an adult with CLL or SLL who has been taking a BTK inhibitor drug for at least a year. You must still have small amounts of cancer cells detectable in your body, but you should generally be feeling well enough to carry out daily activities.
Participants will receive Epcoritamab, an immunotherapy drug designed to help your body's own immune system find and destroy cancer cells. You will be monitored closely by the research team to see how your body responds to this treatment.
The study is currently recruiting new participants and is taking place in Cincinnati, Ohio. It is classified as a Phase 2 study, meaning researchers are further evaluating how well this treatment works.
- 1Tests an immunotherapy drug called Epcoritamab.
- 2Specifically for patients who have residual cancer cells after initial therapy.
- 3Requires you to have been on a BTK inhibitor for at least 12 months.
- 4Located at a medical facility in Cincinnati, Ohio.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.